Paracetamol Safety Backed By Council Of Europe
Executive Summary
Council of Europe Directorate EDQM finds popular paracetamol products sold in the Netherlands and manufactured in China do not contain unsafe levels of a possible human carcinogen as reported in the Dutch media.
You may also be interested in...
EU Regulatory Round-Up: COVID-19 Continuity, Ibuprofen Warnings, Nitrosamines, Ranitidine
The latest EU OTC regulatory news: the EMA with EC and NCAs publish COVID-19 Business Continuity Plan; the CMDh decides to implement the PRAC's recommendations for ibuprofen and ketoprofen; the EMA and HMAs learn lessons from N-nitrosamine impurities in sartans; and the CHMP revisits its opinion on ranitidine following a request by a manufacturer.
Dutch Regulator Backs Paracetamol Safety After Possible Carcinogen Detected
Netherlands' Medicines Evaluation Board says the safety of paracetamol is "not up for debate" after a media investigation reported contamination of the drug with a possible human carcinogen.
EMA Advocates Suspension Of All Ranitidine Drugs In EU
Concerns over the presence of a probable human carcinogen will likely see marketing of all ranitidine-containing drugs suspended across the European Union.